KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Change in Inventory (2016 - 2025)

Pacific Biosciences Of California (PACB) has 15 years of Change in Inventory data on record, last reported at -$3.5 million in Q4 2025.

  • For Q4 2025, Change in Inventory rose 50.42% year-over-year to -$3.5 million; the TTM value through Dec 2025 reached $1.4 million, down 82.94%, while the annual FY2025 figure was $1.4 million, 82.94% down from the prior year.
  • Change in Inventory reached -$3.5 million in Q4 2025 per PACB's latest filing, down from $1.1 million in the prior quarter.
  • Across five years, Change in Inventory topped out at $13.3 million in Q1 2023 and bottomed at -$9.0 million in Q4 2023.
  • Average Change in Inventory over 5 years is $3.5 million, with a median of $2.9 million recorded in 2021.
  • Peak YoY movement for Change in Inventory: soared 1888.65% in 2022, then tumbled 185.47% in 2023.
  • A 5-year view of Change in Inventory shows it stood at $7.7 million in 2021, then skyrocketed by 37.66% to $10.5 million in 2022, then crashed by 185.47% to -$9.0 million in 2023, then increased by 21.47% to -$7.1 million in 2024, then surged by 50.42% to -$3.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Inventory were -$3.5 million in Q4 2025, $1.1 million in Q3 2025, and $1.3 million in Q2 2025.